Adherence to an Annual PSA Screening Program over 3 Years for Brothers and Sons of Men with Prostate Cancer

European Urology

Volumn 45, Issue 3, 2004, Pages 280-286

  Roumier, Xavier ^a   Azzouzi, Rahmene ^b   Valéri, Antoine ^c   Guillemin, Francis ^d   Fournier, Georges ^c   Cussenot, Olivier ^e   Mangin, Philippe ^f   Cormier, Luc ^f  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c Brest Teaching Hospitals   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e HÔPITAL TENON   (France)

^f CHU NANCY BRABOIS   (France)

Author keywords

Adherence; Familial; Heredity; Prostate cancer; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ANXIETY; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILY; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HUMAN; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RELATIVE; SCREENING TEST;

EID: 1242338033     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.09.022     Document Type: Article

References (30)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52:2002;23-47.
2. Dijkman G.A., Debruyne F.M. Epidemiology of prostate cancer. Eur. Urol. 30:1996;281-295.
3. Carter B.S., Bova G.S., Beaty T.H., Steinberg G.D., Childs B., Isaacs W.B.et al. Hereditary prostate cancer: epidemiologic and clinical features. J. Urol. 150:1993;797-802.
4. Bratt O. Hereditary prostate cancer. BJU Int. 85:2000;611-613.
5. Smith R.A., Mettlin C.J., Davis K.J., Eyre H. American Cancer Society guidelines for the early detection of cancer. CA Cancer J. Clin. 50:2000;34-49.
6. Barry M.J. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N. Engl. J. Med. 344:2001;1373-1377.
7. Schroder F.H., Roobol-Bouts M., Vis A.N., van der Kwast T., Kranse R. Prostate-specific antigen-based early detection of prostate cancer validation of screening without rectal examination. Urology. 57:2001;83-90.
8. Laara D., Day N., Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programs. Lancet. 30:1987;1247-1249.
9. Curry S.J., Emmons K.M. Theoretical models for predicting and improving compliance with breast cancer screening. Ann. Behav. Med. 16:1994;302-316.
10. Weinrich S.P., Weinrich M.C., Boyd M.D., Atkinson C. The impact of prostate cancer knowledge on cancer screening. Oncol. Nurs. Forum. 25:1998;527-534.
11. Weinrich S.P., Reynolds W.A. Jr., Tingen M.S., Starr C.R. Barriers to prostate cancer screening. Cancer Nurs. 23:2000;117-121.
12. Miller S.M., Diefenbach M.A., Kruus L.K., Watkins-Bruner D., Hanks G.E., Engstrom P.F. Psychological and screening profiles of first-degree relatives of prostate cancer patients. J. Behav. Med. 24:2001;247-258.
13. Berthon P., Valeri A., Cohen-Akenine A., Drelon E., Paiss T., Wohr G.et al. Predisposing gene for early onset prostate cancer localised on chromosome 1q 42.2-43. Am. J. Hum. Genet. 62:1998;1416-1424.
14. Bruchon-Schweitzer M, Paulhan I. Inventaire d'anxiété état-trait forme Y. Adaptation française. Paris: Centre de Psychologie Appliquée; 1993.
15. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific; 1994.
16. SAS/STAT User's guide, Version 6, Fourth Edition. Cary (NC): 1989.
17. American Urological Association. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Huntingt) 2000;14:267-72, 77-8. 280 passim.
18. American Cancer Society. Prevention and early detection. American Cancer Society. 2002. http://www.cancer.org .
19. Andrykowki M., Carpenter J., Studts J., Cordova M., Cunninghan L., Mager W.et al. Adherence for clinical follow-up after benign breast biopsy. Breast Cancer Res. Treat. 69:2001;165-178.
20. Maule W. Screening for colorectal cancer. N. Engl. J. Med. 21:2002;1672-1673.
21. Cormier L., Reid K., Kwan L., Litwin M.S. Screening behavior in brothers and sons of men with prostate cancer. J. Urol. 169:2003;1715-1719.
22. Cormier L, Azzouzi R, Valéri A, Gundesli M, Moineau MP, Cussenot O, et al. Prostate cancer knowledge and screening behavior in first-degree relatives of men with prostate cancer. J Urol 2002;167.
23. Cormier L., Guillemin F., Valéri A., Fournier G., Cussenot O., Mangin P.et al. The impact of prostate cancer screening on health-related quality of life in at-risk families. Urology. 59:2002;901-906.
24. Kash K., Holland J., Halper M., Miller D. Psychological distress and surveillance behaviors of women with a family history of breast cancer. J. Natl. Cancer Inst. 84:1992;24-30.
25. Bratt O., Damber J.E., Emanuelsson M., Kristoffersson U., Lundgren R., Olsson H.et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur. J. Cancer. 36:2000;235-241.
26. Williams S., Weinman J., Dale J. Doctor-patient communication and patient satisfaction: a review. Fam. Pract. 15:1998;480-492.
27. Fang J., Metter E.J., Landis P., Chan D.W., Morrell C.H., Carter H.B. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 58:2001;411-416.
28. Rietbergen J.B., Kranse R., Hoedemaeker R.F., Kruger A.E., Bangma C.H., Kirkels W.J.et al. Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population- based screening study. Urology. 52:1998;237-246.
29. Azzouzi R., Cormier L., Valéri A., Fournier G., Mangin P., Berthon P.et al. Relevance of PSA-Nanotest on capillary blood in organized mass screening of prostate cancer. Eur. Urol. Suppl. 1(1):2002;96. [Abstract 376].
30. Burke W., Daly M., Garber J., Botkin J., Kahn M.et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA. 277:1997;997.